GC Genome Registers Trademark for Genetic Testing Tracking Indicator 'G-Tracker'

[Asia Economy Reporter Lee Gwan-ju] GC Genome, a clinical genome analysis specialist company, announced on the 27th that it has completed the trademark registration of the genetic test tracking indicator 'G-Tracker.'

'G-Tracker' is a customized specimen verification system for genetic testing, first introduced domestically by GC Genome. It is effectively used to prevent incorrect test results from being delivered to examinees by tracking specimen mix-ups or contamination errors that can frequently occur during genetic testing.

Currently, GC Genome has applied 'G-Tracker' to several NGS (Next Generation Sequencing) tests, including its representative health checkup genetic tests 'Genome Health' and 'Genome Screen,' the obstetrics prenatal fetal chromosome abnormality screening test 'G-NIPT,' and the homologous recombination deficiency test 'GreenPlan HRD,' which can assist in selecting targeted therapies for ovarian cancer. The company explained that this has effectively reduced errors in test result reporting.

Ki Chang-seok, CEO of GC Genome, said, “By introducing the genetic test tracking indicator 'G-Tracker,' we can prevent serious errors such as specimen mix-ups and track specimens throughout the entire testing process, allowing real-time error detection and rapid problem resolution. Through this, we expect to contribute to quality control of testing and enhancement of patient safety.”

Meanwhile, GC Genome, as a clinical genome analysis specialist company, changed its name from GC Green Cross Genome in April to establish its identity and clarify its corporate image.

This content was produced with the assistance of AI translation services.